News and Announcements
Latest Letter to SUDA Shareholders
- Published October 15, 2015 12:53PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
15th October 2015, ASX Announcement
SUDA Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, today published a shareholder newletter, which will be mailed to shareholders who have requested hard copies.
Mr Stephen Carter, Chief Executive Officer of SUDA said: “The newsletter is a valuable forum for us to put recent news in context; to highlight upcoming events; and to set out in more detail some of the exciting assets and activities at SUDA”.
Stories include:
- Upcoming Events
- Westcoast’s core business continues to outperform
- Successful ArTiMistTM publication strategy
- New ArTiMistTM patent granted in South africa
- ZolpiMistTM market research
- Plus more stories
To view the latest newsletter, please click here.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
